These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 31894310

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Down-regulation of PAX6 by promoter methylation is associated with poor prognosis in non small cell lung cancer.
    Zhang X, Yang X, Wang J, Liang T, Gu Y, Yang D.
    Int J Clin Exp Pathol; 2015; 8(9):11452-7. PubMed ID: 26617874
    [Abstract] [Full Text] [Related]

  • 7. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
    Miao Y, Wang L, Zhang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y, Wang E.
    PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
    [Abstract] [Full Text] [Related]

  • 8. Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.
    Kim JS, Han J, Shim YM, Park J, Kim DH.
    Cancer; 2005 Nov 01; 104(9):1825-33. PubMed ID: 16177988
    [Abstract] [Full Text] [Related]

  • 9. Promoter methylation of BRMS1 correlates with smoking history and poor survival in non-small cell lung cancer patients.
    Yang J, Shen Y, Liu B, Tong Y.
    Lung Cancer; 2011 Nov 01; 74(2):305-9. PubMed ID: 21726917
    [Abstract] [Full Text] [Related]

  • 10. TGFBI Promoter Methylation is Associated with Poor Prognosis in Lung Adenocarcinoma Patients.
    Seok Y, Lee WK, Park JY, Kim DS.
    Mol Cells; 2019 Feb 28; 42(2):161-165. PubMed ID: 30726660
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Frequent epigenetic inactivation of deleted in lung and esophageal cancer 1 gene by promoter methylation in non-small-cell lung cancer.
    Zhang Y, Miao Y, Yi J, Wang R, Chen L.
    Clin Lung Cancer; 2010 Jul 01; 11(4):264-70. PubMed ID: 20630829
    [Abstract] [Full Text] [Related]

  • 13. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
    Dötsch MM, Kloten V, Schlensog M, Heide T, Braunschweig T, Veeck J, Petersen I, Knüchel R, Dahl E.
    Epigenetics; 2015 Jul 01; 10(10):903-12. PubMed ID: 26252352
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
    Mastoraki S, Balgkouranidou I, Tsaroucha E, Klinakis A, Georgoulias V, Lianidou E.
    Mol Oncol; 2021 Sep 01; 15(9):2412-2422. PubMed ID: 33159839
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
    Harada H, Miyamoto K, Yamashita Y, Taniyama K, Mihara K, Nishimura M, Okada M.
    Cancer Med; 2015 Oct 01; 4(10):1536-46. PubMed ID: 26276761
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.